State of New Jersey Common Pension Fund D Sells 2,117 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS)

State of New Jersey Common Pension Fund D lessened its position in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 17.6% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 9,893 shares of the company’s stock after selling 2,117 shares during the period. State of New Jersey Common Pension Fund D’s holdings in Krystal Biotech were worth $1,801,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. Crossmark Global Holdings Inc. raised its position in shares of Krystal Biotech by 25.8% in the 3rd quarter. Crossmark Global Holdings Inc. now owns 2,186 shares of the company’s stock worth $398,000 after acquiring an additional 449 shares in the last quarter. TimesSquare Capital Management LLC increased its holdings in Krystal Biotech by 37.6% in the third quarter. TimesSquare Capital Management LLC now owns 114,222 shares of the company’s stock worth $20,792,000 after purchasing an additional 31,183 shares in the last quarter. Janney Montgomery Scott LLC lifted its stake in Krystal Biotech by 17.1% in the third quarter. Janney Montgomery Scott LLC now owns 37,047 shares of the company’s stock valued at $6,744,000 after buying an additional 5,415 shares during the period. First Trust Direct Indexing L.P. bought a new position in shares of Krystal Biotech during the 3rd quarter worth approximately $252,000. Finally, New York State Teachers Retirement System grew its position in shares of Krystal Biotech by 6.6% during the 3rd quarter. New York State Teachers Retirement System now owns 15,879 shares of the company’s stock worth $2,890,000 after buying an additional 979 shares during the period. Institutional investors and hedge funds own 86.29% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on KRYS. Evercore ISI increased their target price on shares of Krystal Biotech from $201.00 to $206.00 and gave the stock an “outperform” rating in a research note on Monday, August 12th. Chardan Capital raised their target price on Krystal Biotech from $153.00 to $208.00 and gave the company a “buy” rating in a research note on Monday, August 5th. Stifel Nicolaus upped their price target on Krystal Biotech from $204.00 to $220.00 and gave the stock a “buy” rating in a research note on Wednesday, September 11th. William Blair upgraded Krystal Biotech to a “strong-buy” rating in a report on Friday, August 30th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Krystal Biotech in a report on Thursday, August 29th. One analyst has rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $197.00.

Krystal Biotech Stock Up 2.9 %

KRYS stock opened at $175.64 on Tuesday. The firm has a market capitalization of $5.05 billion, a PE ratio of 96.46 and a beta of 0.82. Krystal Biotech, Inc. has a twelve month low of $99.00 and a twelve month high of $219.34. The stock’s 50 day moving average is $180.83 and its 200-day moving average is $181.79.

Krystal Biotech (NASDAQ:KRYS) last posted its quarterly earnings data on Monday, November 4th. The company reported $0.91 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.84 by $0.07. The firm had revenue of $83.84 million for the quarter, compared to the consensus estimate of $82.94 million. Krystal Biotech had a net margin of 21.68% and a return on equity of 7.54%. The business’s revenue for the quarter was up 879.9% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.67) EPS. On average, equities research analysts anticipate that Krystal Biotech, Inc. will post 2.97 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $197.76, for a total value of $4,944,000.00. Following the completion of the transaction, the insider now owns 1,500,882 shares in the company, valued at $296,814,424.32. This represents a 1.64 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 14.10% of the stock is currently owned by insiders.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).